Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Clinuvel Pharmaceuticals Limited (CLVLF – Research Report), Medibank Private Ltd. (MDBPF – Research Report) and Innate Pharma SA (IPHYF – Research Report).
Clinuvel Pharmaceuticals Limited (CLVLF)
Wilsons analyst Melissa Benson maintained a Buy rating on Clinuvel Pharmaceuticals Limited on June 26 and set a price target of A$30.07. The company’s shares closed last Tuesday at $12.00, close to its 52-week low of $11.00.
According to TipRanks.com, Benson is a 1-star analyst with an average return of
Clinuvel Pharmaceuticals Limited has an analyst consensus of Moderate Buy, with a price target consensus of $19.94.
See Insiders’ Hot Stocks on TipRanks >>
Medibank Private Ltd. (MDBPF)
In a report issued on June 27, Kieran Chidgey from Jarden maintained a Buy rating on Medibank Private Ltd., with a price target of A$3.80. The company’s shares closed last Tuesday at $2.05, close to its 52-week high of $2.10.
According to TipRanks.com, Chidgey is a 4-star analyst with an average return of
Medibank Private Ltd. has an analyst consensus of Moderate Buy, with a price target consensus of $2.41.
Innate Pharma SA (IPHYF)
Kepler Capital analyst Justine Telliez maintained a Hold rating on Innate Pharma SA on June 26 and set a price target of EUR3.10. The company’s shares closed last Wednesday at $3.36.
According to TipRanks.com, Telliez is ranked #6108 out of 8474 analysts.
Currently, the analyst consensus on Innate Pharma SA is a Hold with an average price target of $3.39.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
